Bering Capital is a venture capital firm that specializes in biotech and medical technology investments. The firm typically participates in later-stage funding rounds, such as Series C, and engages in investments that support the development and commercialization of advanced medical technologies and biotechnologies.

Notable portfolio companies include OncoResponse, which has raised $54.6 million. Bering Capital's investment philosophy focuses on fostering innovation in the medical technology sector. The firm offers unique value-add services, including strategic guidance and industry connections, to help portfolio companies navigate regulatory landscapes and accelerate their growth.